Financial Performance - The company's operating revenue for Q3 2023 reached ¥571,176,343.36, representing a 108.21% increase compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was -¥82,106,803.14 for Q3 2023, with a year-to-date net profit of -¥219,964,027.34[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥31,483,643.75 for Q3 2023, showing significant improvement[5]. - The company reported a net cash flow from operating activities of -¥373,677,900.53 year-to-date, indicating ongoing cash flow challenges[5]. - The company reported a total of 271,212,760 shares held by the largest shareholder, accounting for 60.90% of total shares[10]. - The company reported a gross profit margin of approximately 3.5% for Q3 2023, down from 6.5% in Q3 2022, reflecting a decline in profitability[17]. - The net loss for Q3 2023 was ¥220,383,751.08, an improvement compared to a net loss of ¥403,460,333.75 in Q3 2022, showing a reduction of about 45.2%[19]. - In Q3 2023, the company reported a net loss attributable to the parent company of CNY -220,031,701.72, compared to a loss of CNY -402,620,817.82 in the same period last year, indicating an improvement of approximately 45%[20]. - The basic and diluted earnings per share for Q3 2023 were both CNY -0.49, an improvement from CNY -0.92 in Q3 2022[20]. Research and Development - Research and development expenses totaled ¥316,969,129.31 for Q3 2023, accounting for 55.49% of operating revenue, indicating a 17.61% increase in R&D investment[5]. - The R&D investment increased significantly as several products entered critical clinical stages, leading to higher funding requirements[8]. - R&D expenses in Q3 2023 amounted to ¥806,115,168.18, up from ¥605,125,368.48 in Q3 2022, reflecting a growth of approximately 33.2%[19]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[19]. Assets and Liabilities - The total assets of the company as of the end of Q3 2023 were ¥2,847,595,362.67, reflecting a 4.08% increase from the end of the previous year[5]. - Total assets as of Q3 2023 were ¥2,847,595,362.67, slightly up from ¥2,735,875,608.33 in the previous year, marking an increase of approximately 4.1%[16]. - Total liabilities increased to ¥3,286,694,027.77 in Q3 2023 from ¥2,978,066,553.77 in Q3 2022, representing a rise of about 10.3%[16]. - The company's equity attributable to shareholders was reported at -¥433,138,935.20 in Q3 2023, worsening from -¥236,650,939.28 in Q3 2022[16]. - Short-term borrowings rose to ¥827,419,033.27 in Q3 2023, compared to ¥508,449,216.36 in Q3 2022, indicating an increase of approximately 62.8%[16]. Cash Flow and Investments - Cash inflow from operating activities totaled CNY 1,399,193,356.76, a significant increase from CNY 715,295,203.21 in the previous year, representing a growth of approximately 95%[21]. - The net cash outflow from operating activities was CNY -373,677,900.53, slightly worse than the previous year's outflow of CNY -365,865,528.04[21]. - Investment activities generated a net cash outflow of CNY -412,354,804.44, compared to CNY -667,727,629.82 in the same period last year, showing a reduction in cash outflow by approximately 38%[23]. - The company raised CNY 1,358,027,023.53 through financing activities, an increase from CNY 730,365,853.82 in the previous year, marking an increase of about 86%[23]. - The total cash and cash equivalents at the end of Q3 2023 stood at CNY 409,079,124.06, up from CNY 300,797,066.69 at the end of Q3 2022[23]. - The company received CNY 1,033,000,000.00 from investment recoveries, down from CNY 2,111,000,000.00 in the previous year, indicating a decrease of approximately 51%[21]. - The company reported a total cash outflow from investment activities of CNY 1,449,003,026.78, compared to CNY 2,782,373,035.21 in the same period last year, reflecting a decrease of about 48%[23]. Market and Strategic Focus - The company’s revenue growth was driven by strong market expansion and competitive advantages in production capacity and cost[8]. - The company continues to focus on expanding its market presence and enhancing its product pipeline to drive future growth[8]. - The company has not disclosed any new product or technology developments in this quarter[12]. - There are no significant mergers or acquisitions reported during this period[12]. - The company has not provided specific future guidance or market expansion strategies in the current report[12].

证券代码：688520 证券简称：神州细胞 公告编号：2023-034 北京神州细胞生物技术集团股份公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 10 月 30 日(星期一) 至 11 月 03 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sinocelltech.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2023 年 10 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2023 年第三季度 报告。为便于广大投资者更全面深入地了解公司 2023 年第三季度经营成果、财 务状况，公司计划于 2023 年 11 月 06 日上午 10:00-11:00 举行 202 ...

中信证券股份有限公司关于 北京神州细胞生物技术集团股份公司 2023 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京神州细 胞生物技术集团股份公司（以下简称"神州细胞"或"公司"）持续督导阶段的保荐机 构，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）等相关规定，出具 2023 年半年度（以下简称"本持续 督导期"）持续督导跟踪报告。 1 一、持续督导工作情况 序号 工作内容 实施情况 1 建立健全并有效执行持续督导工作制度，并针对具体的持 续督导工作计划制定相应的工作计划 保荐机构已建立健全并有效 执行了持续督导制度，并制 定了相应的工作计划 2 根据中国证监会相关规定，在持续督导工作开始前，与上 市公司签署持续督导协议，明确双方在持续督导期间的权 利义务，并报上海证券交易所备案 保荐机构已与神州细胞签订 承销及保荐协议，该协议明 确了双方在持续督导期间的 权利和义务，并已报上海证 券交易所备案 3 持续督导期间，按照有关规定对上市公司违法违规事项公 开发表声明的，应于披露前向上海证券交易所报告，并经 上海 ...

证券代码：688520 证券简称：神州细胞 公告编号：2023-033 重要内容提示： （http://roadshow.sseinfo.com/） 投资者可于 2023 年 9 月 6 日(星期三)16:00 前通过公司电话或邮箱 ir@sinocelltech.com 将需要了解和关注的问题提前提供给公司。公司将在说明会 上对投资者普遍关注的问题进行回答。 北京神州细胞生物技术集团股份公司（以下简称"公司"）已于 2023 年 8 月 23 日在上海证券交易所网站（www.sse.com.cn）披露了公司 2023 年半年度报 告。为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状 况、发展理念，公司参与了由上交所主办的 2023 年半年度制药及生物制品行业 集体业绩说明会，此次活动将采用网络文字互动的方式举行，投资者可登录上海 证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以网络文字互动方式召开，公司将针对 2023 年半年度的 经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露 ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[2]. - The company reported a significant increase in revenue, achieving a total of 500 million in the first half of 2023, representing a 25% growth compared to the same period last year[12]. - Total revenue for the first half of 2023 reached CNY 808.08 million, representing a year-on-year growth of 114.91%[48]. - The company's operating revenue for the first half of 2023 reached ¥808,075,290.81, an increase of 114.91% compared to ¥376,009,837.38 in the same period last year[72]. - The net profit attributable to shareholders was a loss of ¥137,857,224.20, an improvement from a loss of ¥250,341,256.26 in the previous year[17]. - The company reported a net profit margin of 15% for the first half of 2023, indicating improved operational efficiency[12]. - The net cash flow from operating activities was a negative ¥175,233,048.38, compared to a negative ¥240,169,415.35 in the same period last year[17]. - The company's cash and cash equivalents decreased by 43.22% to ¥551,866,933.04, down from ¥971,884,878.41[75]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 1.2 million users by the end of June 2023[2]. - User data showed a 30% increase in active users, reaching 1.2 million by the end of June 2023[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[2]. - The company is focusing on market expansion in Europe, targeting a 15% increase in market penetration by the end of 2024[12]. Research and Development - Research and development expenses increased by 30% to 100 million CNY, focusing on the development of new biopharmaceutical products[2]. - Research and development expenses increased by 10%, totaling 50 million, reflecting the company's commitment to innovation[12]. - The company reported a total R&D investment of approximately ¥547.62 million, a 39.70% increase compared to ¥392.01 million in the same period last year[38]. - The company's R&D expenditure accounted for 67.77% of its revenue, a decrease of 36.49 percentage points from 104.26% in the previous year[19]. - The company has 791 R&D personnel, representing 38.23% of the total workforce, an increase from 716 personnel in the same period last year[43]. - The average salary for R&D personnel increased to 14.03 thousand CNY, up from 13.44 thousand CNY in the previous year[43]. Product Development and Approvals - New product launches included a novel antibody therapy, expected to enter clinical trials by Q4 2023, which could expand the company's market share significantly[12]. - The company has launched 1 recombinant protein drug and 3 monoclonal antibody products, with 2 vaccine products included for emergency use[21]. - The product Anjain® (recombinant human coagulation factor VIII) was approved for additional indications in January 2023, targeting bleeding control in children with hemophilia A[21]. - The COVID-19 vaccine SCTV01E has been included for emergency use in both China and the UAE, with positive results from clinical trials indicating good efficacy against Omicron variants[22]. - The company has launched two biosimilars, Anjairun® and Anbeizhu®, in June 2023, with approvals for multiple indications[22]. - The company has completed communication with the National Medical Products Administration regarding the Phase III clinical research plan for the SCT1000 project (14-valent HPV vaccine) and is currently preparing for patient enrollment[23]. - The SCT-110A product (PD-1 monoclonal antibody) has completed patient enrollment for two indications: first-line treatment of liver cancer and head and neck cancer[23]. - The SCT650C product (IL-17 monoclonal antibody injection) has obtained Phase Ia clinical trial filing in Australia and has initiated patient enrollment[23]. - The company has established a production line with a total capacity of 22,000L for commercial production, with an additional 20,000L production line under construction[25]. Strategic Partnerships and Acquisitions - A strategic partnership was established with a leading biotechnology firm to enhance product development capabilities[2]. - The company announced a strategic partnership with a leading biotech firm to enhance its product pipeline and accelerate development timelines[12]. - The company is exploring potential acquisitions to strengthen its position in the oncology market, with a budget of up to 200 million allocated for this purpose[12]. Compliance and Governance - The company has no significant risks impacting its operations during the reporting period, ensuring stable performance[4]. - There were no non-operational fund occupations by controlling shareholders or related parties during the reporting period[5]. - The board of directors confirmed that all members attended the board meeting, ensuring governance compliance[4]. - The company is committed to improving corporate governance and compliance awareness among employees to support long-term development[56]. Environmental and Social Responsibility - The company has updated its emergency response plan for environmental incidents and has filed it with government departments, conducting regular drills to mitigate impacts[92]. - The company has implemented real-time monitoring for wastewater pollutants, including COD and ammonia nitrogen, and conducted multiple monitoring sessions for various emissions sources[93]. - The company has adopted energy-saving technologies, such as variable frequency air conditioning systems and high-efficiency lighting, to reduce greenhouse gas emissions[95]. - The company has committed to a 36-month lock-up period for its major shareholders following the IPO, ensuring stability in shareholding[97]. Risks and Challenges - The company anticipates continued losses in the second half of 2023 due to ongoing investments in R&D and marketing for new products[58]. - The company is facing risks related to market competition and pricing pressures, particularly for its flagship product, Anjain®[60]. - The company faces uncertainties in preclinical research outcomes, which may impact the ability to recover research costs and affect financial performance[61]. - The company is facing risks related to raw material shortages and is working on improving supply chain management to ensure stable procurement[65]. Shareholder Commitments and Stability - The actual controller, Xie Liangzhi, has committed not to transfer or entrust the management of shares held before the IPO for 36 months from the date of listing[99]. - The controlling shareholder, Lasa Ailike, has made a similar commitment regarding share transfers for 36 months post-listing[99]. - The company has received commitments from multiple shareholders to not transfer shares for specified periods, ensuring stability post-IPO[106]. - The company will bear legal responsibility for any losses incurred due to violations of these commitments[104]. Financial Management and Fund Utilization - The total amount of funds raised for the clinical research projects reached CNY 1,676,530,000, with cumulative investment of CNY 848,786,252.98, achieving a progress rate of 102.05%[177]. - The company has committed to improving its fund management practices to prevent similar errors in the future[180]. - The company has not reported any other significant issues regarding the use of raised funds during the reporting period[181].

证券代码：688520 证券简称：神州细胞 公告编号： 2023-032 北京神州细胞生物技术集团股份公司 2023年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京神州细胞生物技术集团股份公司（以下简称"公司"）董事会根据《上市公 司监管指引第2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科 创板上市公司自律监管指引第1号——规范运作》等有关规定，编制了截至 2023年 6月 30 日的《2023年半年度募集资金存放与实际使用情况的专项报告》，内容如下： 一、募集资金基本情况 行人民币普通股（A 股）股票 1,000.00 万股，股票面值为人民币 1 元，发行价格为每股人 民币48.33元。本次向特定对象发行股票募集资金总额为人民币483,300,000.00元，扣除承 销费人民币5,500,000.00元（含增值税）后，实际收到募集资金人民币477,800,000.00 元， 募集资金总额扣除发行费用人民币11,865,624.11元（不含增值税）后，实 ...

证券代码：688520 证券简称：神州细胞 公告编号：2023-031 北京神州细胞生物技术集团股份公司 第二届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 表决结果：同意 3 票， 反对 0 票， 弃权 0 票。 北京神州细胞生物技术集团股份公司（以下简称"公司"）第二届监事会第 七次会议于 2023 年 8 月 22 日在公司会议室以现场及通讯方式召开，本次会议的 通知于 2023 年 8 月 11 日通过电子邮件方式送达全体监事。本次会议应出席监事 3 人，实际到会监事 3 人。本次会议由监事会主席李汛先生主持，会议的召集和 召开程序符合《中华人民共和国公司法》《北京神州细胞生物技术集团股份公司 章程》（以下简称"《公司章程》"）以及其他有关法律法规、规范性文件的规 定。 二、监事会会议审议情况 经与会监事充分讨论，会议以投票表决方式审议通过了如下议案： （一）审议通过《关于北京神州细胞生物技术集团股份公司 2023 年半年度 报告及摘要的议案》 监事会认为：公司 ...

证券代码：688520 证券简称：神州细胞 公告编号：2023-030 北京神州细胞生物技术集团股份公司 关于更换保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为保证持续督导工作的有序进行，中信证券现委派焦延延先生（简历见附件） 接替王志宏先生担任公司的保荐代表人，继续履行持续督导职责。本次更换后， 公司再融资项目持续督导期间的保荐代表人为焦延延先生和邵才捷女士，持续督 导期至中国证券监督管理委员会和上海证券交易所规定的持续督导义务结束为 止。 附件： 焦延延先生简历 焦延延先生，保荐代表人、注册会计师，现任中信证券投资银行管理委员会 执行总经理。曾负责或参与裕同科技、华大基因、绿色动力、赛诺医疗、诺禾致 源、康希诺生物、科美诊断、义翘神州、联影医疗 IPO 项目；深科技、环旭电 子、裕同科技、华大基因、神州细胞再融资项目。焦延延先生在保荐业务执业过 程中严格遵守《证券发行上市保荐业务管理办法》等相关规定，执业记录良好。 公司董事会对王志宏先生在公司再融资项目及持续督导期间所做的工作表 示衷心感谢！ 特 ...

Financial Performance - The company achieved operating revenue of CNY 1,023.18 million during the reporting period, with a net loss attributable to shareholders of CNY 518.99 million[4]. - The net loss attributable to shareholders, excluding non-recurring gains and losses, was CNY 395.68 million[4]. - The company's revenue for 2022 reached approximately ¥1.02 billion, representing a 661.33% increase compared to ¥134.39 million in 2021[23]. - The net loss attributable to shareholders decreased to approximately ¥519.00 million in 2022 from ¥866.85 million in 2021[23]. - The net cash flow from operating activities improved to approximately -¥427.91 million in 2022, compared to -¥862.82 million in 2021[24]. - The total assets increased by 99.24% to approximately ¥2.74 billion at the end of 2022, up from ¥1.37 billion at the end of 2021[24]. - The company reported a basic earnings per share of -¥1.19 for 2022, an improvement from -¥1.99 in 2021[25]. - The company reported a net cash outflow from operating activities of CNY -427,909,674.49, an improvement from the previous year's outflow[126]. - The company achieved total revenue of CNY 1,023,176,678.65, representing a year-on-year growth of 661.33%[124]. - The net loss attributable to the parent company was CNY 51,899,580, a reduction of 40.13% compared to the previous year[124]. Research and Development - The company reported a total R&D investment of CNY 973.45 million in 2022, focusing on preclinical research and clinical trials[3]. - The company is committed to continuous investment in clinical and preclinical research to maintain its competitive edge in the biopharmaceutical industry[3]. - The company’s R&D expenditure accounted for 95.14% of its revenue in 2022, highlighting a significant investment in innovation[25]. - The company has 20 academic papers published in important domestic and international journals, showcasing strong research capabilities in basic research and clinical applications[41]. - The company has established a comprehensive R&D and production platform for recombinant proteins, monoclonal antibodies, and innovative vaccines, enhancing its competitive edge in the biopharmaceutical industry[71]. - The company has completed preclinical development and production of 3 neutralizing antibodies and 5 recombinant protein vaccines since early 2020, demonstrating advanced R&D speed and efficiency[81]. - The company has developed advanced detection technologies and quality analysis systems for complex biopharmaceuticals, ensuring high-quality production processes[82]. - The company has established a financial management system to ensure timely and accurate reporting, complying with regulatory requirements for fundraising[187]. - The company has invested significantly in preclinical and clinical research to enhance product competitiveness, although there are inherent risks in achieving expected clinical outcomes[113]. Product Development and Pipeline - The company is actively expanding its product pipeline and increasing R&D investments as products enter critical clinical research phases[4]. - The company reported a significant focus on innovative drugs, including monoclonal antibodies and bispecific antibodies, which are expected to enhance treatment efficacy in various diseases[13]. - The company is actively engaged in the development of biosimilars, which are expected to provide cost-effective alternatives to existing biologic therapies, enhancing market competitiveness[14]. - The company is developing SCT1000, the world's first 14-valent HPV vaccine, which covers all 12 high-risk HPV types and is currently preparing for Phase III clinical trials expected to complete enrollment by the end of 2023[72]. - The company has established a comprehensive marketing organization with over 100 distributors nationwide, focusing on both direct delivery and commercial distribution channels[59]. - The company has a rich product pipeline, with 1 recombinant protein drug and 1 monoclonal antibody product approved for market, and 2 COVID-19 vaccine products included in emergency use[108]. - The company is focused on expanding its international business, adapting its strategies to different regulatory environments and market conditions to maximize economic and social benefits[118]. Market and Competitive Landscape - The company continues to face cumulative unabsorbed losses and is expected to incur further losses in the near future[4]. - The company is facing risks related to ongoing losses and the potential for delisting if it fails to achieve profitability or if accumulated losses continue to grow[108]. - The company faces intense competition in the innovative drug market, with potential competitors developing superior products that could significantly impact its market position[116]. - The biopharmaceutical industry is facing challenges from strict regulations and rapid technological advancements, necessitating continuous innovation and adaptation from companies[69]. - The company is actively managing risks related to raw material shortages and price fluctuations, ensuring stable supplier relationships to avoid disruptions in operations[117]. Strategic Initiatives and Future Outlook - The company plans to continue expanding its market presence and product offerings, focusing on innovative therapies and strategic partnerships[26]. - Future outlook includes expanding the product portfolio with new drug applications, particularly in oncology and autoimmune disease treatments, aiming for a broader market reach[14]. - The company is exploring partnerships and collaborations to accelerate market expansion and leverage complementary technologies in drug development[14]. - The company plans to increase investment in the research and development of biopharmaceuticals and vaccines over the next decade, aiming for international market entry[181]. - The company is committed to enhancing its information technology infrastructure to improve operational efficiency and internal control[189]. Governance and Management - The company’s governance structure complies with relevant laws and regulations, ensuring that all shareholders, especially minority shareholders, can exercise their voting rights effectively[191]. - The company’s board of directors actively participates in meetings and committees, ensuring informed decision-making and protection of shareholder interests[192]. - The company has a diverse management team with a mix of genders and ages, promoting inclusivity in its leadership[196]. - The company is committed to long-term growth and stability, as indicated by the retention of key management personnel and their ongoing development[195].

Financial Performance - The company's operating revenue for Q1 2023 was ¥328,779,509.01, representing a significant increase of 111.02% compared to the same period last year[4]. - The net profit attributable to shareholders of the listed company was a loss of ¥153,011,423.00, with a net profit excluding non-recurring gains and losses of a loss of ¥58,524,478.28[4]. - The company's net loss for Q1 2023 was ¥153,769,208.59, compared to a net loss of ¥118,198,000.00 in Q1 2022, representing a worsening of 30.1%[19]. - The net profit for Q1 2023 was -153,348,003.27 CNY, compared to -143,622,878.13 CNY in Q1 2022, indicating a year-over-year increase in losses of approximately 7.5%[21]. - The company reported a total comprehensive income of -153,348,003.27 CNY for Q1 2023, compared to -143,622,878.13 CNY in Q1 2022, reflecting a decline in overall financial performance[21]. Cash Flow - The net cash flow from operating activities was negative at ¥121,991,794.43[4]. - Cash flow from operating activities showed a net outflow of -121,991,794.43 CNY, worsening from -95,350,434.30 CNY in Q1 2022[23]. - The cash flow from investing activities resulted in a net outflow of -517,667,554.98 CNY, compared to -387,170,845.31 CNY in the previous year[24]. - The net cash flow from financing activities was -51,177,831.75 RMB, compared to 351,747,155.74 RMB in the previous year, indicating a substantial decline[32]. - The company reported a total cash outflow from operating activities of 11,025,610.45 RMB, compared to 10,068,905.02 RMB in the same quarter last year, an increase of approximately 9.5%[31]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,877,949,104.54, reflecting a 5.19% increase from the end of the previous year[5]. - Total liabilities rose to ¥3,266,245,838.84 in Q1 2023, up from ¥2,978,066,553.77 in Q1 2022, marking an increase of 9.7%[17]. - The total equity attributable to shareholders decreased to -¥382,420,147.87 as of March 31, 2023, from -¥236,650,939.28 at the end of 2022, indicating a decline of 61.6%[18]. - The company's total assets decreased to CNY 3,196,335,084.75 as of March 31, 2023, down from CNY 3,254,225,625.01 at the end of 2022, reflecting a decline of 1.77%[28]. - The total owner's equity decreased to CNY 2,571,237,580.62 as of March 31, 2023, down from CNY 2,582,956,396.48 at the end of 2022, a decline of 0.43%[28]. Research and Development - Research and development expenses totaled ¥270,002,471.74, which is an increase of 43.20% year-on-year[4]. - The ratio of R&D expenses to operating revenue was 82.12%, a decrease of 38.89 percentage points compared to the previous year[5]. - R&D expenses in Q1 2023 amounted to ¥248,165,462.86, compared to ¥184,747,212.74 in Q1 2022, indicating a rise of 34.3%[19]. - Research and development expenses decreased to CNY 1,405,310.16 in Q1 2023, down 49.5% from CNY 2,781,699.28 in Q1 2022[29]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,145[10]. - The company reported a basic and diluted earnings per share of -0.34 CNY for Q1 2023, slightly worse than -0.33 CNY in Q1 2022[22]. Government Support - The company received government subsidies amounting to ¥5,849,022.36 during the quarter[6]. Inventory and Borrowings - The company's inventory increased to ¥208,846,931.26 as of March 31, 2023, from ¥191,883,056.14 at the end of 2022, an increase of 8.9%[16]. - Short-term borrowings increased to ¥599,346,189.30 in Q1 2023, compared to ¥508,449,216.36 in Q1 2022, reflecting an increase of 17.9%[17].